EGA
PTCT icon

Eagle Global Advisors’s PTC Therapeutics PTCT Stock Holding History

Eagle Global Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-67,750
Closed -$949K – 402
2016
Q3 		$949K Buy
67,750
+38,880
+135% +$316K 0.03% 150
2016
Q2 		$203K Buy
+28,870
New +$212K 0.01% 323

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Eagle Global Advisors's PTCT Position: Q4 2016 in Review

Eagle Global Advisors sold out of PTC Therapeutics (PTCT) in Q4 2016, closing a stake of 67,750 shares — an estimated $949K sold.

Eagle Global Advisors first reported a position in PTCT in Q2 2016 and held it in 2 quarters. The position peaked at $949K in Q3 2016. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

  • Eagle Global Advisors reported no remaining PTC Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 67,750 PTC Therapeutics shares in Q4 2016, an estimated $949K.
  • Eagle Global Advisors first reported a position in PTC Therapeutics in Q2 2016 and held it in 2 quarters.
  • Eagle Global Advisors's PTC Therapeutics position peaked at $949K in Q3 2016.
  • 123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on Eagle Global Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.